Aytu Biopharma, Inc
AYTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385818
No open-market purchases or sales by Aytu Biopharma, Inc insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q3 2026, worth $7.95M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $28.9M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −2 vs. previous quarter
- 35
- 13F valueReported value at the end of Q3 2026
- $7.95M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $57.6M
- −13.3% year over year
- Net income, FY2026
- -$14.3M
- No comparable prior period
- Free cash flow, FY2026
- $3.25M
- No comparable prior period
- Revenue, Q1 FY2027
- $14.8M
- +6.9% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2026: $14.3M (24.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 301.7K
- Shares sold short
- Change
- −27.2K
- −8.3% vs. previous
- Days to cover
- 11.65
- At average daily volume
Superinvestors holding AYTU, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding AYTU at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aytu Biopharma, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Disbrow JarrettChief Business Officer | PPurchase | +16.7K | $1.50 | +$25.0K | +130.2%29.5K after | |
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Disbrow Joshua R.Chief Executive Officer | PPurchase | +66.7K | $1.50 | +$100.0K | +77.0%153.3K after | |
| Jun 9, 2025 (view filing)4:31 PM ET | Jun 6 | 3 days | Nantahala Capital Management, LLC and 2 others10% Owner | PPurchase | +4.00M | $1.50 | +$6.00M | –4.82M after | Derivative |
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +15.0K | $1.30 | +$19.5K | +21.0%86.6K after | |
| Jun 20, 2023 (view filing) | Jun 16 | 4 days | Pyszczymuka GregChief Commerical Officer | PPurchase | +12.0K | $1.87 | +$22.4K | +120.8%21.9K after | |
| Jun 15, 2023 (view filing) | Jun 14 | 1 day | Disbrow Joshua R.Chief Executive Officer | PPurchase | +14.0K | $1.86 | +$26.0K | +24.3%71.6K after | |
| Dec 21, 2022 (view filing)9:17 AM ET | Dec 19 | 2 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +112.4K | $0.2229 | +$25.0K | +10.0%1.23M after | |
| Dec 21, 2022 (view filing)9:15 AM ET | Dec 19 | 2 days | Pyszczymuka GregChief Commercial Officer | PPurchase | +100.0K | $0.2448 | +$24.5K | +121.9%182.1K after | |
| Nov 28, 2022 (view filing)4:30 PM ET | Nov 18 | 10 days | Oki Mark KChief Financial Officer | PPurchase | +90.0K | $0.23 | +$20.7K | +90.0%190.0K after | Amended |
| Nov 28, 2022 (view filing)4:30 PM ET | Nov 18 | 10 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +222.0K | $0.237 | +$52.6K | +24.7%1.12M after | Amended |
Top 10 13F holders, Q3 2026
See all 35 holdersThe largest institutional positions in Aytu Biopharma, Inc at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1,086,812 | $2.33M | 0.13% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 964,900 | $2.06M | 1.72% | +51,979+5.7% | Added |
| AWM Investment Company, Inc. | 619,574 | $1.33M | 0.13% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 261,146 | $558.9K | 0.00% | 00.0% | Unchanged |
| Crown Advisors Management, Inc. | 200,000 | $428.0K | 0.30% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 123,670 | $264.7K | 0.00% | +30,023+32.1% | Added |
| Renaissance Technologies LLC | 121,623 | $260.3K | 0.00% | +16,800+16.0% | Added |
| Diadema Partners LP | 67,186 | $143.8K | 0.05% | −81,360−54.8% | Reduced |
| Two Sigma Investments, LP | 65,513 | $140.2K | 0.00% | −39,813−37.8% | Reduced |
| Dimensional Fund Advisors LP | 50,046 | $107.1K | 0.00% | +4,720+10.4% | Added |
Holders of 5% or more of AYTU
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aytu Biopharma, Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 13D/A | 14.40%1.09M shares | – | May 26, 20234 filings | Jun 9, 2025 | SEC |
| Stonepine Capital Management, LLC | 13G/A | 9.90%906.1K shares | – | Feb 12, 20216 filings | Aug 13, 2025 | SEC |
| AWM Investment Company, Inc. | 13G/A | 5.80%619.6K shares | −1.10 ppfrom 6.90% | Aug 14, 20252 filings | Feb 13, 2026 | SEC |